Edition:
United Kingdom

People: BioXcel Therapeutics Inc (BTAI.OQ)

BTAI.OQ on NASDAQ Stock Exchange Capital Market

11.09USD
18 Sep 2019
Change (% chg)

$0.11 (+1.00%)
Prev Close
$10.98
Open
$11.00
Day's High
$11.31
Day's Low
$10.61
Volume
17,848
Avg. Vol
13,427
52-wk High
$11.94
52-wk Low
$2.41

Sharma, Vikas 

Dr. Vikas Sharma is Vice President - Business Development of the Company. Dr. Sharma has over 12 years of experience in business development activities across the pharma landscape. He has led multiple complex deals that involved upfront, milestone and royalty payments. Most recently Dr. Sharma was the director, business development at MacroGenics where he played an instrumental role in leading licensing deals with companies such as Incyte Corporation, Roche, and Janssen Pharmaceuticals. Prior to joining MacroGenics, Dr. Sharma served as the director, business development at Rexahn Pharmaceuticals where he led the due diligence and execution of licensing deals, M&A as well as capital markets transactions. Previously, he served as manager, business development for MedImmune (the global biologics business of AstraZeneca), where he executed multiple licensing transactions. Prior to that, Dr. Sharma served in a business development role with increasing responsibilities at Children's Hospital of Philadelphia, Bradley Pharmaceuticals and Advanced Bioadjuvant. Dr. Sharma earned a second master's degree and a doctorate in biology from Rutgers University. He completed his bachelor's degree and master's degree in microbiology from the University of Mumbai, India. He has authored multiple peer-reviewed publications and conference presentations.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --